{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:33:05Z","timestamp":1785429185435,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Open Fund Project of First-Class Disciplines of Hunan University of Chinese Medicine","award":["2022ZYX04"],"award-info":[{"award-number":["2022ZYX04"]}]},{"name":"The Key Discipline Construction Project of Ophthalmology of Traditional Chinese Medicine of the National Administration of Traditional Chinese Medicine","award":["ZK1801YK015"],"award-info":[{"award-number":["ZK1801YK015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03299-z","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:02:33Z","timestamp":1725523353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Jie","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuHui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"3299_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH (2023) The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol 949:175586. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586","journal-title":"Eur J Pharmacol"},{"issue":"3\u20134","key":"3299_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08977194.2022.2074843","volume":"40","author":"AG Goswami","year":"2022","unstructured":"Goswami AG, Basu S, Huda F et al (2022) An appraisal of vascular endothelial growth factor (VEGF): The dynamic molecule of wound healing and its current clinical applications. Growth Fact 40(3\u20134):73\u201388. https:\/\/doi.org\/10.1080\/08977194.2022.2074843","journal-title":"Growth Fact"},{"issue":"10","key":"3299_CR3","doi-asserted-by":"publisher","first-page":"17347","DOI":"10.18632\/oncotarget.14468","volume":"8","author":"B Zhang","year":"2017","unstructured":"Zhang B, Wang D, Ji TF, Shi L, Yu JL (2017) Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-\u03baB signaling pathway in a rat model. Oncotarget 8(10):17347","journal-title":"Oncotarget"},{"issue":"2","key":"3299_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/ijms23020931","volume":"23","author":"SA Dabravolski","year":"2022","unstructured":"Dabravolski SA, Khotina VA, Omelchenko AV, Kalmykov VA, Orekhov AN (2022) The role of the VEGF family in atherosclerosis development and its potential as treatment targets. Int J Mol Sci 23(2):931. https:\/\/doi.org\/10.3390\/ijms23020931","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3299_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01310-7","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li Y, Wang Y et al (2022) Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol 15(1):1\u201328. https:\/\/doi.org\/10.1186\/s13045-022-01310-7","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3299_CR6","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.3390\/ijms22105387","volume":"22","author":"THV Le","year":"2022","unstructured":"Le THV, Kwon SM (2022) Vascular endothelial growth factor biology and its potential as a therapeutic target in rheumatic diseases. Int J Mol Sci 22(10):5387. https:\/\/doi.org\/10.3390\/ijms22105387","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3299_CR7","doi-asserted-by":"publisher","first-page":"11041","DOI":"10.1038\/s41598-022-15227-1","volume":"12","author":"R Belvedere","year":"2022","unstructured":"Belvedere R, Novizio N, Morello S, Petrella A (2022) The combination of mesoglycan and VEGF promotes skin wound repair by enhancing the activation of endothelial cells and fibroblasts and their cross-talk. Sci Rep 12(1):11041. https:\/\/doi.org\/10.1038\/s41598-022-15227-1","journal-title":"Sci Rep"},{"issue":"1","key":"3299_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/ijms19010275","volume":"19","author":"JW Shim","year":"2018","unstructured":"Shim JW, Madsen JR (2018) VEGF signaling in neurological disorders. Int J Mol Sci 19(1):275. https:\/\/doi.org\/10.3390\/ijms19010275","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3299_CR9","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.18632\/oncotarget.14020","volume":"8","author":"R Hua","year":"2017","unstructured":"Hua R, Qing L, Wong IYH, Ning H, Wang H (2017) Choroidal microvascular proliferation secondary to diabetes mellitus. Oncotarget 8(2):2034","journal-title":"Oncotarget"},{"issue":"24","key":"3299_CR10","doi-asserted-by":"publisher","first-page":"9752","DOI":"10.3390\/ijms21249752","volume":"21","author":"EG Jensen","year":"2020","unstructured":"Jensen EG, Jakobsen TS, Thiel S, Askou AL, Corydon TJ (2020) Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration. Int J Mol Sci 21(24):9752. https:\/\/doi.org\/10.3390\/ijms21249752","journal-title":"Int J Mol Sci"},{"key":"3299_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2019.02.038","volume":"204","author":"AJ Rong","year":"2022","unstructured":"Rong AJ, Swaminathan SS, Vanner EA, Parrish RK II (2022) Predictors of neovascular glaucoma in central. Am J Ophthalmol 204:62\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.038","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3299_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/157016111795495503","volume":"9","author":"S Thanigaimani","year":"2011","unstructured":"Thanigaimani S, Kichenadasse GA, Mangoni A (2011) The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 9(3):358\u2013380. https:\/\/doi.org\/10.2174\/157016111795495503","journal-title":"Curr Vasc Pharmacol"},{"key":"3299_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2021.104207","volume":"138","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yao Y, Li R et al (2023) Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF\/6A cells. Microvasc Res 138:104207. https:\/\/doi.org\/10.1016\/j.mvr.2021.104207","journal-title":"Microvasc Res"},{"issue":"1","key":"3299_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-022-00969-2","volume":"67","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto Y, Okada A, Matsui H, Yasunaga H, Aihara M, Obata R (2023) Recent trends in anti-vascular endothelial growth factor intravitreal injections: A large claims database study in Japan. Jpn J Ophthalmol 67(1):109\u2013118. https:\/\/doi.org\/10.1007\/s10384-022-00969-2","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"3299_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001205","volume":"8","author":"A Hatamnejad","year":"2022","unstructured":"Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N (2022) Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol 8(1):e001205. https:\/\/doi.org\/10.1136\/bmjophth-2022-001205","journal-title":"BMJ Open Ophthalmol"},{"issue":"5","key":"3299_CR16","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s40123-023-00768-z","volume":"12","author":"PJ Patel","year":"2023","unstructured":"Patel PJ, Villavicencio P, Hanumunthadu D (2023) Systematic review of neovascular age-related macular degeneration disease activity criteria use to shorten, maintain or extend treatment intervals with anti-VEGF in clinical trials: implications for clinical practice. Ophthalmol Ther 12(5):2323\u20132346. https:\/\/doi.org\/10.1007\/s40123-023-00768-z","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"3299_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ (2023) Real-world outcomes of anti-vegf therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther 12(2):809\u2013826. https:\/\/doi.org\/10.1007\/s40123-023-00672-6","journal-title":"Ophthalmol Ther"},{"key":"3299_CR18","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1016\/j.ejphar.2023.175586","volume":"16","author":"YS Yuen","year":"2022","unstructured":"Yuen YS, Tan GSW, Gan NYA et al (2022) Real-world evidence in the management of diabetic macular edema with intravitreal anti-VEGFs in Asia: a systematic literature review. Clin Ophthalmol 16:3503\u20133526. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586","journal-title":"Clin Ophthalmol"},{"key":"3299_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","volume":"11","author":"A Ninkov","year":"2022","unstructured":"Ninkov A, Frank JR, Maggio LA (2022) Bibliometrics: methods for studying academic publishing. Perspect Med Educ 11:173\u2013176. https:\/\/doi.org\/10.1007\/s40037-021-00695-4","journal-title":"Perspect Med Educ"},{"key":"3299_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11845-018-1936-5","volume":"188","author":"E Roldan-Valadez","year":"2019","unstructured":"Roldan-Valadez E, Salazar-Ruiz SY, Rafael I-C et al (2019) Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago journal rank, source-normalised impact per paper, H-index, and alternative metrics. Ir J Med Sci 188:939\u2013951. https:\/\/doi.org\/10.1007\/s11845-018-1936-5","journal-title":"Ir J Med Sci"},{"key":"3299_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.5195\/jmla.2023.1513","volume":"111","author":"P Kokol","year":"2023","unstructured":"Kokol P (2023) Discrepancies among Scopus and Web of Science, coverage of funding information in medical journal articles: a follow-up study. J Med Libr Assoc 111:703\u2013708. https:\/\/doi.org\/10.5195\/jmla.2023.1513","journal-title":"J Med Libr Assoc"},{"key":"3299_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","volume":"110","author":"H Arruda","year":"2022","unstructured":"Arruda H, Silva ER, Lessa M et al (2022) VOSviewer and Bibliometrix. J Med Libr Assoc 110:392\u2013395. https:\/\/doi.org\/10.5195\/jmla.2022.1434","journal-title":"J Med Libr Assoc"},{"issue":"3","key":"3299_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/prm2.12099","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xu Z, Wang Q, Zhang Z, Tang D, Zhao J (2023) Metrology and visualization analysis of literatures related to tumor immunotherapy based on CiteSpace. Precision Med Sci 12(3):159\u2013169. https:\/\/doi.org\/10.1002\/prm2.12099","journal-title":"Precision Med Sci"},{"issue":"6","key":"3299_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00484-023-02466-8","volume":"67","author":"O Motlogeloa","year":"2023","unstructured":"Motlogeloa O, Fitchett JM (2023) Climate and human health: a review of publication trends in the international journal of Biometeorolog. Int J Biometeorol 67(6):933\u2013955. https:\/\/doi.org\/10.1007\/s00484-023-02466-8","journal-title":"Int J Biometeorol"},{"issue":"4","key":"3299_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s11846-020-00380-6","volume":"15","author":"F D\u00edez-Mart\u00edn","year":"2023","unstructured":"D\u00edez-Mart\u00edn F, Blanco-Gonz\u00e1lez A, Prado-Rom\u00e1n C (2023) The intellectual structure of organizational legitimacy research: a co-citation analysis in business journals. Rev Manag Sci 15(4):1007\u20131043. https:\/\/doi.org\/10.1007\/s11846-020-00380-6","journal-title":"Rev Manag Sci"},{"issue":"5","key":"3299_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1108\/00220411011066790","volume":"66","author":"M Norris","year":"2010","unstructured":"Norris M, Oppenheim C (2010) The h-index: a broad review of a new bibliometric indicator. J Doc 66(5):681\u2013705. https:\/\/doi.org\/10.1108\/00220411011066790","journal-title":"J Doc"},{"key":"3299_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s11192-014-1315-6","volume":"101","author":"JP Qiu","year":"2014","unstructured":"Qiu JP, Dong K, Yu HQ (2014) Comparative study on structure and correlation among author co-occurrence networks in bibliometrics. Scientometrics 101:1345\u20131360. https:\/\/doi.org\/10.1007\/s11192-014-1315-6","journal-title":"Scientometrics"},{"issue":"4","key":"3299_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3163\/1536-5050.103.4.014","volume":"103","author":"CW Belter","year":"2015","unstructured":"Belter CW (2015) Bibliometric indicators: opportunities and limits. J Med Libr Assoc JMLA 103(4):219. https:\/\/doi.org\/10.3163\/1536-5050.103.4.014","journal-title":"J Med Libr Assoc JMLA"},{"issue":"20","key":"3299_CR29","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/nejmoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GA, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908. https:\/\/doi.org\/10.1056\/nejmoa1102673","journal-title":"N Engl J Med"},{"issue":"12","key":"3299_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"issue":"7","key":"3299_CR31","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"issue":"4","key":"3299_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039","journal-title":"Ophthalmology"},{"issue":"13","key":"3299_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/nejmoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193\u20131203. https:\/\/doi.org\/10.1056\/nejmoa1414264","journal-title":"N Engl J Med"},{"issue":"1","key":"3299_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"issue":"6","key":"3299_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Elman MJ, Aiello LP, Beck RW et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):1064\u20131077. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.031","journal-title":"Ophthalmology"},{"issue":"2","key":"3299_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145(2):239\u2013248. https:\/\/doi.org\/10.1016\/j.ajo.2007.10.004","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3299_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43\u201358. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3299_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six\u2013week results of the VIEW studies. Ophthalmology 121(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011","journal-title":"Ophthalmology"},{"key":"3299_CR39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s11192-016-2111-2","volume":"109","author":"W Marx","year":"2016","unstructured":"Marx W, Bornmann L (2016) Change of perspective: bibliometrics from the point of view of cited references\u2014a literature overview on approaches to the evaluation of cited references in bibliometrics. Scientometrics 109:1397\u20131415. https:\/\/doi.org\/10.1007\/s11192-016-2111-2","journal-title":"Scientometrics"},{"issue":"14","key":"3299_CR40","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"issue":"14","key":"3299_CR41","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"3299_CR42","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615\u2013625"},{"issue":"3","key":"3299_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2015","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin Ma\u2019an Giust AAANMJ (2015) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363\u2013372. https:\/\/doi.org\/10.1016\/j.ophtha.2005.11.019","journal-title":"Ophthalmology"},{"key":"3299_CR44","doi-asserted-by":"publisher","unstructured":"Yang J, Cheng C, Shen S, Yang S (2017) Comparison of complex network analysis software: citespace, SCI 2 and Gephi [C]. In: 2017 IEEE 2nd International conference on Big data analysis 2:169\u2013172. https:\/\/doi.org\/10.1109\/ICBDA.2017.8078800","DOI":"10.1109\/ICBDA.2017.8078800"},{"key":"3299_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910444","volume":"13","author":"L Song","year":"2022","unstructured":"Song L, Zhang J, Ma D et al (2022) A bibliometric and knowledge-map analysis of macrophage polarization in atherosclerosis from 2001 to 2021. Front Immunol 13:910444. https:\/\/doi.org\/10.3389\/fimmu.2022.910444","journal-title":"Front Immunol"},{"issue":"3","key":"3299_CR46","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","volume":"30","author":"JU Yoon","year":"2010","unstructured":"Yoon JU, Byun YJ, Koh HJ (2010) Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 30(3):418\u2013424. https:\/\/doi.org\/10.1097\/IAE.0b013e3181bd2fe4","journal-title":"Retina"},{"key":"3299_CR47","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2147\/NDT.S400923","volume":"19","author":"K Zhou","year":"2023","unstructured":"Zhou K, Zhou Y, Zeng Y et al (2023) Research hotspots and global trends of transcranial direct current stimulation in stroke: a bibliometric analysis. Neuropsychiatr Dis Treat 19:601\u2013613. https:\/\/doi.org\/10.2147\/NDT.S400923","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3299_CR48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/JPR.S403648","volume":"16","author":"J Yang","year":"2023","unstructured":"Yang J, Jiang T, Xu G, Liu W (2023) Bibliometrics analysis and visualization of sarcopenia associated with osteoporosis from 2000 to 2022. J Pain Res 16:821\u2013837. https:\/\/doi.org\/10.2147\/JPR.S403648","journal-title":"J Pain Res"},{"key":"3299_CR49","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2147\/OPTH.S305141","volume":"23","author":"F Horner","year":"2021","unstructured":"Horner F, Lip PL, Mohammed BR et al (2021) Comparing effectiveness of three different anti-vegf treatment regimens for neovascular age-related macular degeneration: two years\u2019 real-world clinical outcomes. Clin Ophthalmol 23:1703\u20131713. https:\/\/doi.org\/10.2147\/OPTH.S305141","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"3299_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F et al (2022) YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci 2(1):100111. https:\/\/doi.org\/10.1016\/j.xops.2021.100111","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"3299_CR51","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3390\/ijerph19042303","volume":"19","author":"M Musia\u0142-Kopiejka","year":"2022","unstructured":"Musia\u0142-Kopiejka M, Polanowska K, Dobrowolski D et al (2022) The effectiveness of brolucizumab and aflibercept in patients with neovascular age-related macular degeneration. Int J Environ Res Public Health 19(4):2303. https:\/\/doi.org\/10.3390\/ijerph19042303","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"3299_CR52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3389\/fphar.2022.1017889","volume":"12","author":"C Iovino","year":"2020","unstructured":"Iovino C, Mastropasqua R, Lupidi M et al (2020) Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature. Pharmaceutics 12(8):703. https:\/\/doi.org\/10.3389\/fphar.2022.1017889","journal-title":"Pharmaceutics"},{"issue":"8","key":"3299_CR53","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.ejphar.2023.175586","volume":"15","author":"C Zhou","year":"2023","unstructured":"Zhou C, Lei F, Sharma J et al (2023) Sustained inhibition of VEGF and TNF-\u03b1 achieves multi-ocular protection and prevents formation of blood vessels after severe ocular trauma. Pharmaceutics 15(8):2059. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586","journal-title":"Pharmaceutics"},{"key":"3299_CR54","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.1016\/j.ejphar.2023.175586","volume":"13","author":"P Ma","year":"2022","unstructured":"Ma P, Pan X, Liu R et al (2022) Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Front Pharmacol 13:1017889. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175586","journal-title":"Front Pharmacol"},{"key":"3299_CR55","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.3390\/pharmaceutics12080703","volume":"16","author":"M Xu","year":"2022","unstructured":"Xu M, Fan R, Fan X, Shao Y, Li X (2022) Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis. Drug Des, Devel Ther 16:3241\u20133262. https:\/\/doi.org\/10.3390\/pharmaceutics12080703","journal-title":"Drug Des, Devel Ther"},{"issue":"61B","key":"3299_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/pharmaceutics15082059","volume":"33","author":"A Sharma","year":"2021","unstructured":"Sharma A, Banait S (2021) Anti-VEGF therapy in ophthalmology. J Pharm Res Int 33(61B):91\u201397. https:\/\/doi.org\/10.3390\/pharmaceutics15082059","journal-title":"J Pharm Res Int"},{"key":"3299_CR57","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.2147\/IJN.S418115","volume":"18","author":"J Cao","year":"2023","unstructured":"Cao J, Zhang F, Xiong W (2023) Discovery of aptamers and the acceleration of the development of targeting research in ophthalmology. Int J Nanomed 18:4421\u20134430. https:\/\/doi.org\/10.2147\/IJN.S418115","journal-title":"Int J Nanomed"},{"issue":"13","key":"3299_CR58","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2017.18391","volume":"319","author":"AL Beam","year":"2018","unstructured":"Beam AL, Kohane IS (2018) Big data and machine learning in health care. JAMA 319(13):1317\u20131318. https:\/\/doi.org\/10.1001\/jama.2017.18391","journal-title":"JAMA"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03299-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03299-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03299-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:42:20Z","timestamp":1741880540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03299-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03299-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"368"}}